Abstract: Provided herein is a method for the treatment and/or prophylaxis of a cancer associated with galectin-1. The method includes administering to a subject a pharmaceutical composition that mainly composed of ganoderic acid S (GAS) and ganoderic acid T (GAT). The method further includes administering to the subject another anti-cancer agent before, together with, or after the administration of the present pharmaceutical composition, so as to synergistically suppress the growth of the cancer.
Abstract: Disclosed herein is a novel use of a polysaccharide mixture for the treatment of hyperglycemia and/or disorders related thereto (e.g., diabetes mellitus). The polysaccharide mixture comprises about 30-50% (wt %) of ?(1?3) glucan and ?(1?6) glucan, and has a molecular weight of at least 500,000. The polysaccharide mixture may be administered to a subject suffering from hyperglycemia in a dose of about 1 to 1,000 mg/Kg to ameliorate or alleviate symptoms associated with hyperglycemia.
Abstract: Disclosed herein is a novel use of a polysaccharide mixture for the treatment of hyperglycemia and/or disorders related thereto (e.g., diabetes mellitus). The polysaccharide mixture comprises about 30-50% (wt %) of ?(1?3) glucan and ?(1?6) glucan, and has a molecular weight of at least 500,000. The polysaccharide mixture may be administered to a subject suffering from hyperglycemia in a dose of about 1 to 1,000 mg/Kg to ameliorate or alleviate symptoms associated with hyperglycemia.
Abstract: Disclosed herein are compositions and methods for the treatment or prophylaxis of a subject having or susceptible to a kidney disease. The method includes the step of administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg to improve the glomerular filtration rate (GFR) of the subject for at least 4 folds as compared to the GFR of the subject before treatment, The method further includes the step of administering to the subject an effective amount of lucidenic acid C (LAC), lucidenic acid N (LAN), lucidenic acid E2 (LAE2), lucidenic acid A (LAA), and lucidenic acid D2 (LAD2).
Type:
Application
Filed:
June 9, 2014
Publication date:
December 10, 2015
Applicant:
Trineo Biotechnology Co. LTD.
Inventors:
Cheng-Po Huang, Teng-Hai Chen, Kuang Dee Chen, Chun-Tao Su